Navigation Links
Watson Files FDA Application for Generic LYBREL(R)
Date:3/13/2008

atements. Actual results may differ materially from Watson's current expectations depending upon a number of factors affecting Watson's business. These factors include, among others, patents and other intellectual property rights held by competitors and other third parties and the uncertainty of the outcome of litigation related to such patents and intellectual property rights; the difficulty of predicting the timing or outcome of product development efforts and FDA or other regulatory agency approvals or actions; the impact of competitive products and pricing; market acceptance of and continued demand for Watson's products; difficulties or delays in manufacturing; and other risks and uncertainties detailed in Watson's periodic public filings with the Securities and Exchange Commission, including but not limited to Watson's Annual Report on Form 10-K for the year ended December 31, 2007. Lybrel(R) is a registered trademark of Wyeth.

(Logo: http://www.newscom.com/cgi-bin/prnh/20020214/WATSONLOGO)


'/>"/>
SOURCE Watson Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Barr Subsidiary Sues Watson for SEASONIQUE(R) Patent Infringement
2. Watson Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Results; Provides 2008 Outlook
3. Watson to Present at the 2008 Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference
4. Warner Chilcott and Watson Pharmaceuticals Announce Launch of Tilia(TM) Fe
5. Watson Receives FDA Approval for Generic Accuneb(R)
6. Watson to Present at the Bear Stearns 20th Annual Healthcare Conference
7. CryoCor Files Patent Infringement Lawsuits Against CryoCath
8. Omeros Corporation Files Registration Statement for Proposed Initial Public Offering
9. TAP Pharmaceutical Products Inc. Files New Drug Application for TAK-390MR in Patients with Acid-Related Disorders
10. Lexicon Files Investigational New Drug Application for LX1032 as a Potential Treatment for Carcinoid Syndrome
11. Roche Files IND for Second Genmab Antibody
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/19/2014)... 19, 2014 Shimadzu Scientific Instruments ... Prominence-i and Nexera-i, adding to the company’s extensive ... functionality, an intuitive operating environment, and full automation, ... efficient workflow for conventional to ultra-high-speed analysis. ... and intelligent design so users can begin building ...
(Date:8/19/2014)... (PRWEB) August 19, 2014 ... to raise $200,000 to fund a corporate lab ... , This development is a critical component ... of care to the implementation of personalized medicine ... of practicing medicine. , Indiegogo contributions will support ...
(Date:8/19/2014)... Lenexa, KS (PRWEB) August 19, 2014 ... to offer fast and cost-effective metabolite production from ... and proprietary chemistry platform, the technology enables convenient ... issues. According to XenoTech’s Vice President of ... metabolite synthesis for assessing clinical risk can be ...
(Date:8/19/2014)... In November 2012, the European Union (EU) mandated ... in a new PSUR – responding to the increasing need ... a drug. Adopted in many regions, the main objectives of ... comprehensive and critical analysis of new or emerging information on ... new evidence of the potential benefits of a drug; and ...
Breaking Biology Technology:Shimadzu’s New i-Series Integrated Liquid Chromatography Systems Provide Laboratories Wider Range of Analytical Capabilities 2Shimadzu’s New i-Series Integrated Liquid Chromatography Systems Provide Laboratories Wider Range of Analytical Capabilities 3Cellgen Diagnostics Launches Indiegogo Crowdfunding Campaign for DNA Medical Testing Device 2Cellgen Diagnostics Launches Indiegogo Crowdfunding Campaign for DNA Medical Testing Device 3Beyond Metabolite Identification, Testable Quantities Now Offered by XenoTech 2Beyond Metabolite Identification, Testable Quantities Now Offered by XenoTech 3Top Five Best Practices for Developing Your Periodic Benefit Risk Evaluation Report (PBRER), New Webinar Hosted by Xtalks 2
... , , FLAGSTAFF, Ariz., July 24 ... Australia, New Zealand, Great Britain, Myanmar, the Philippines and Indonesia are ... Radisson Woodlands Hotel to share research findings that will determine the ... , On Sunday morning, Mayor Sara Presler will ...
... ... spaces leased to biotech, pharma and medical devices tenants are faring better in some markets ... ... recession, the credit crunch, pharmaceuticals industry mergers and an overall slump in the commercial property ...
... , , ... PROLOR Biotech, Inc. (OTC Bulletin Board: PBTH), formerly Modigene Inc., today announced ... up to $10 million of the company,s newly issued 10% cumulative convertible preferred ... agreements, the company closed on the issuance of one million preferred shares for ...
Cached Biology Technology:World Renowned Scientists Gather to Share Latest Information on Answer to Wildlife Reproductive Fertility Control 2Life Sciences Real Estate Outperforming Other Sectors 2Life Sciences Real Estate Outperforming Other Sectors 3PROLOR Biotech Announces $10 Million Preferred Stock Line From Members of The Frost Group 2PROLOR Biotech Announces $10 Million Preferred Stock Line From Members of The Frost Group 3PROLOR Biotech Announces $10 Million Preferred Stock Line From Members of The Frost Group 4
(Date:8/19/2014)... MA -- MIT chemical engineers have devised a new ... are released slowly over a few weeks. When applied ... the body to rapidly form new bone that looks ... type of coated scaffold could offer a dramatic improvement ... involves transplanting bone from another part of the patient,s ...
(Date:8/19/2014)... born with neonatal abstinence syndrome (NAS) secondary to ... going through withdrawal than others, but the underlying ... epigenetic (when genes are turned on or off) ... researchers at Boston University School of Medicine (BUSM) ... of its kind study to identify some of ...
(Date:8/19/2014)... seas during warm phases and became extinct during cold ... a link between marine crocodilian diversity and the evolution ... 140 million years. , The research, led by ... and formerly from the University of Bristol, UK is ... crocodiles are ,cold-blooded, animals that mainly live in fresh ...
Breaking Biology News(10 mins):Engineering new bone growth 2Engineering new bone growth 3In-utero methadone, Subutex exposure could alter gene expression, cause severe Neonatal Abstience Syndrome 2Evolution of marine crocodilians constrained by ocean temperatures 2
... , WALL, N.J., Dec. 21 BIO-key International, ... biometric identification solutions, today announced the appointment of Cecilia ... Ceci replaces Tom Colatosti, BIO-key,s Chairman, who had been ... http://www.newscom.com/cgi-bin/prnh/20050509/BIOKEYLOGO ) , Ceci joined BIO-key in 2007 and ...
... Biometric Society has chosen Springer as the co-publisher of ... (JABES). The quarterly journal will start publication ... 2010. Backfiles to 2001 will be available on ... Journal of Agricultural, Biological, and Environmental Statistics publishes ...
... field, researchers from The University of Western Ontario are studying ... Why is this important? Because the common fruit fly ( ... survive freezing and the little creature just so happens to ... finding a way to freeze them for research purposes is ...
Cached Biology News:BIO-key(R) Appoints Cecilia Welch as Chief Financial Officer 2BIO-key(R) Appoints Cecilia Welch as Chief Financial Officer 3International Biometric Society co-publishes journal with Springer 2The how and why of freezing the common fruit fly 2
Biotin-OSu is used to label proteins, immunological agents, DNA and synthetic oligonucleotides. Biotin labeling is detected through enzymatically labeled avidin or streptavidin proteins that conforma...
RAT ANTI MOUSE JAM-2 Immunogen: Recombinant soluble JAM-2...
...
...
Biology Products: